-
New Hope for Chronic Hepatitis B: Understanding the FDA Approval of Hepcludex (bepirovirsen)
NYSE: $GSK A Significant Milestone in Liver Health The landscape of chronic hepatitis B (CHB) treatment is evolving. Recently, the FDA reached a significant decision regarding Hepcludex (bepirovirsen), providing new options for patients managing this complex viral infection. This development marks a noteworthy step forward in therapeutic approaches for those living with chronic liver disease.…
-
Jemperli (dostarlimab-gxly) Approved in US as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
NYSE: $GSK Philadelphia, PA — October 19 2026 — GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite… Source: Read More
-
New Hope for Lung Cancer Patients: GSK Shares Positive Data on Jideytro (zidesamtinib)
NYSE: $GSK A Major Milestone in ROS1-Positive Lung Cancer GSK has recently announced encouraging registrational data from its clinical trial program for Jideytro (zidesamtinib), a targeted therapy designed for patients living with ROS1-positive non-small cell lung cancer (NSCLC). These results represent a significant step forward in the company’s goal to bring this treatment to patients…
-
A New Hope: FDA Grants Priority Review for Jemperli in Locally Advanced Rectal Cancer
NYSE: $GSK Advancing Treatment for dMMR/MSI-H Rectal Cancer There is promising news in the landscape of oncology as the U.S. Food and Drug Administration (FDA) has officially accepted a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab-gxly). This application has been granted Priority Review, signaling a potential shift in how we approach locally advanced rectal…
-
A Breakthrough in Antibiotic Treatment: FDA Approves UTEBZI for Complicated UTIs
NYSE: $GSK A New Option for Challenging Infections The landscape of antibiotic treatment has evolved with the recent FDA approval of UTEBZI (tebipenem pivoxil hydrobromide). This medication marks a significant advancement as the first oral carbapenem antibiotic approved for the treatment of complicated urinary tract infections (cUTIs) in adults. Understanding UTEBZI UTIs can often be…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-08-2026 TO 02-14-2026
Well well, The Seattle Seahawks take the Win in Super Bowl LX. This is what Google’s Gemini summarized regarding stock market prediction after the Win. And now, back to the BIO-TECH STOCK CATALYST REPORT. We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-01-2026 TO 02-07-2026
The Groundhog sees his shadow, so hunker down and trade more to warm up! 😉 We’re excited to announce the release of our latest bio tech stock catalyst report for the upcoming week. This new stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions…
$AMGN, $AZN, $BMY, $BSX, $DNLI, $GKOS, $GSK, $INCY, $JAZZ, $LLY, $MRNA, $PHVS, $REGN, $SNY, biopharmaceutical, clinical-research, fda, new drug application, pr-newswire, press-releases